Ipratropium Bromide And Albuterol Sulfate Solution
Product Images NDC 0487-0201

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Ipratropium Bromide And Albuterol Sulfate (NDC 0487-0201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nephron Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem Structure (Chemfigure1)

Chemical structures of the active ingredients albuterol sulfate and ipratropium bromide are shown. The left side depicts the albuterol sulfate molecular structure, labeled accordingly. The right side displays the ipratropium bromide molecular structure with appropriate chemical notation.*

FDA Label Image

B5387e98-figure-03 (B5387e98 Figure 03)

A line graph showing percent fractional excretion in liters over hours after dosing for three treatments: Albuterol, Ipratropium, and combined Ipratropium Bromide and Albuterol Sulfate inhalation. The graph illustrates the time course of each treatment's excretion profile from 0 to 8 hours post-dose.*

FDA Label Image

B5387e98-figure-04 (B5387e98 Figure 04)

A data table displaying adverse events occurring in more than 1% of patients in treatment groups receiving Albuterol, Ipratropium, or the combination of Ipratropium Bromide and Albuterol Sulfate. It lists the number of patients and percentage experiencing adverse events in body systems including body as a whole, digestive, musculo-skeletal, respiratory, and urogenital. The combination group generally shows the highest percentages across most adverse event categories.*

FDA Label Image

B5387e98-figure-05 (B5387e98 Figure 05)

An instructional diagram demonstrating the preparation of Ipratropium Bromide and Albuterol Sulfate inhalation solution. It shows a vial being attached to a nebulizer device, indicating how the solution is prepared for respiratory inhalation use.*

FDA Label Image

B5387e98-figure-06 (B5387e98 Figure 06)

An instructional diagram showing the assembly or connection of an inhalation device or nebulizer component. The image features a nozzle or mouthpiece being aligned with an airway adapter or tubing connector, illustrating a step for preparing the respiratory inhalation device for use.*

FDA Label Image

Figure 3 And 4 (Figure34)

Illustrations showing the use of a respiratory inhalation device for Ipratropium Bromide and Albuterol Sulfate solution. Figure 3 depicts a person inhaling through a mouthpiece, while Figure 4 shows a person inhaling through a facemask attached to the device.*

FDA Label Image

Foil Card (276 Foil C)

Label for Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg inhalation solution USP. The prescription sterile solution is supplied as 5 x 3 mL unit-dose vials for oral inhalation. Made by Nephron Pharmaceuticals Corporation, the label includes storage conditions, a barcode, and customer service contact information.*

FDA Label Image

Card Carton 30 (449 New Card)

Label for Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg inhalation solution, USP, by Nephron Pharmaceuticals Corporation. The product is a respiratory inhalation solution provided in 30 x 3 mL sterile unit-dose vials. The label indicates the product is for oral inhalation only and includes active ingredients with strengths of 0.5 mg ipratropium bromide and 3 mg albuterol sulfate equivalent to 2.5 mg albuterol base. Packaging is marked Rx only and made in the USA.*

FDA Label Image

60 Carton (113 Carton)

Packaging label for Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg inhalation solution, USP. The label specifies the product as an oral inhalation solution in sterile unit-dose vials, with a package containing 60 vials of 3 mL each. Manufactured by Nephron Pharmaceuticals Corporation in the USA, the label includes active and inactive ingredient information, usage instructions, and regulatory information.*

FDA Label Image

Single Foil (409 Foil)

Label for Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg inhalation solution, USP in a 3 mL unit-dose vial for oral inhalation only. Manufactured by Nephron Pharmaceuticals Corporation. The label includes patient instructions for use, storage conditions, and a barcode. It specifies the active ingredients, inactive components, and provides guidance on dosage and vial handling.*

FDA Label Image

Single Carton (817 Carton Sing)

Packaging label for Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg inhalation solution, USP, by Nephron Pharmaceuticals Corporation. The label states it is a respiratory (inhalation) solution with 30 unit-dose vials of 3 mL each, Rx only, with dosage equivalent to 2.5 mg albuterol base. The label includes instructions for use, clinical pharmacology, drug interactions, and patient information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.